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A STUDY OF LIPID PROFILE IN CHRONIC KIDNEY DISEASE PATIENTS 
ON CONSERVATIVE  MANAGEMENT ,ON HAEMODIALYSIS AND AFTER 
RENAL TRANSPLANTATION 
Background: 
              Chronic kidney disease [CKD] is associated with specific abnormalities  
in the lipoprotein metabolism both in the early and in the advanced stages of 
chronic renal failure. Regardless of age, heart disease is a major cause of morbidity 
and mortality among patients with renal failure. Our study aimed at to estimate 
lipid profile in CKD patients on conservative management ,on haemodialysis, after 
renal transplantation and to compare with healthy controls. 
 Methods : 
              The  study population was  60 patients with 20 patients in each group and 
20 healthy controls. Each group had 10 males and 10 females without diabetes  or 
hypertension. After 12 hrs fasting serum lipid profile was estimated in all groups. 
 Results : 
             The mean total cholesterol was within optimal level in all the three groups. 
The  mean triglyceride was borderline high in conservative and haemodialysis 
group ,whereas in post transplant group it was high as per ATP III guidelines. The 
mean LDL was optimal in conservative and hemodialysis group, high in post 
transplant group. The mean HDL was decreased in all the three groups. Total 
cholesterol / HDL ratio was increased in all the three groups. 
 Conclusion: 
              From this study it is inferred that dyslipidemia is more common chronic 
kidney disease patients and more marked in renal transplant recipients. 
Keywords: 
    CKD chronic kidney disease, dyslipidemia, ATP III guidelines , haemodialysis, 
renal transplantation. 
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INTRODUCTION 
                 Chronic kidney disease [CKD] is associated with specific 
abnormalities  in the lipoprotein metabolism both in the early and in the 
advanced stages of chronic renal failure. It has been suggested that the renal 
dyslipoproteinaemia of renal insufficiency contributes to the progression of 
glomerular and tubular lesions, with subsequent deterioration of renal 
function. Regardless of age, heart disease is a major cause of morbidity and 
mortality among patients with renal failure. Atherosclerotic heart disease is 
believed to account for approximately 55% of mortality and contributes to a 
20-fold increase in ischemic heart disease and to a 10-fold increase in risk of 
stroke among patients with ESRD (chronic kidney disease stage 5)(8). 
Hypertension and diabetes mellitus, known risk factors for the development 
of cardiovascular disease (CVD) in the general population, are also the most 
common causes for the development of CVD in patients with CKD and 
ESRD. There are several other important risk factors, such as smoking, 
proteinuria, oxidative stress, inflammation and dyslipidemia that 
independently or in combination with elevated blood pressure, can cause 
deterioration in renal function. 
              Diabetic CKD patients have higher TG and lower HDL cholesterol 
than their non-diabetic counterparts, suggesting that diabetes itself 
exacerbates lipid abnormalities in patients with renal impairment. The 
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concentration of lipoproteins in renal failure may be increased as a 
consequence of increased synthesis, decreased catabolism or combination of 
both. Patients on maintenance haemodialysis also have abnormalties in lipid 
metabolism like hypertriglyceridaemia and low HDL which could 
contribute to atherosclerosis and cardiovascular disease. Hyperlipidemia is 
common after renal transplantation with use of immunosuppressive drugs . 
There is increasing evidence that post transplant lipoprotein abnormalities 
may contribute to the development of Cardiovascular disease and shown to 
increase the risk of chronic rejection, altered graft function. Therefore it is 
important to screen all patients with CKD for dyslipidemia and treat them as 
they are considered a very high risk group for CVD. 
              Since hyperlipidemias become more pronounced as renal failure 
advances and can be modulated by therapeutic intervention it is worthwhile 
to study and compare lipid profile abnormalities in renal failure patients on 
different modes of management. 
 A prospective study was taken up, to study the lipid profile in patients of  
chronic renal failure  
a.  on conservative management 
b.  on regular haemodialysis 
c.  after renal transplantation and to compare with healthy controls 
 
  8 
 
       
 
AIM OF THE STUDY 
 
1.  To estimate the levels of 
¾ Serum triglycerides, 
¾ Serum total cholesterol, 
¾ High density lipoprotein cholesterol, 
¾ Low density lipoprotein cholesterol, 
¾ Ratio of total cholesterol to HDL cholesterol level in patients of  
  chronic kidney disease, 
a. On conservative management 
b. On regular haemodialysis 
c.  Following renal transplantation 
2. To compare the lipid profile of the above mentioned patients with that 
of healthy controls.  
3. The principal reason to evaluate dyslipidemia  patients with CKD is to 
detect abnormalities that may be treated to reduce the incidence of 
ACVD.(Atherosclerotic cardiovascular disease )  
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REVIEW OF LITERATURE 
LIPOPROTEINS 
          Lipoproteins are complexes of lipids and proteins that are essential for 
the transport of cholesterol, triglycerides, and fat-soluble vitamins. 
Lipoprotein Classification and Composition 
              Lipoproteins play an essential role in the absorption of dietary 
cholesterol, long-chain fatty acids, and fat-soluble vitamins; the transport of 
triglycerides, cholesterol, and fat-soluble vitamins from the liver to 
peripheral tissues; and the transport of cholesterol from peripheral tissues to 
the liver. 
              Lipoproteins contain a core of hydrophobic lipids (triglycerides and 
cholesteryl esters) surrounded by hydrophilic lipids (phospholipids, 
unesterified cholesterol) and proteins that interact with body fluids. The 
plasma lipoproteins are divided into five major classes based on their 
relative density : 
1. Chylomicrons,  
2. Very low-density lipoproteins (VLDLs), 
3.  Intermediate-density lipoproteins (IDLs), 
4.  Low-density lipoproteins (LDLs), and 
5.  High-density lipoproteins (HDLs). 
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  Each lipoprotein class comprises a family of particles that vary 
slightly in density, size and protein composition. The density of a 
lipoprotein is determined by the amount of lipid per particle. HDL is the 
smallest and most dense lipoprotein, whereas chylomicrons and VLDLs are 
the largest and least dense lipoprotein particles. Most plasma triglyceride is 
transported in chylomicrons or VLDLs, and most plasma cholesterol is 
carried as cholesteryl esters in LDLs and HDLs. 
CHYLOMICRONS AND VERY LOW DENSITY LIPOPROTEINS 
            By definition, chylomicrons are found in chyle formed only by the 
lymphatic system draining the intestine. They are responsible for the 
transport of all dietary lipids into the circulation. Small quantities of VLDL 
are also to be found in chyle; however, most of the plasma VLDL are of 
hepatic origin. They are the vehicles of transport of triacylglycerol from the 
liver to the extrahepatic tissues. 
            There are striking similarities in the mechanisms of formation of 
chylomicrons by intestinal cells and of VLDL by hepatic parenchymal cells  
perhaps because apart  from the mammary gland the intestine and liver are 
the only tissues from which particulate lipid is secreted. Newly secreted or 
“nascent” chylomicrons and VLDL contain only a small amount of 
apolipoproteins C and E, and the full complement is acquired from HDL in 
the circulation. Apo B is essential for chylomicron and VLDL formation. 
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               Triacylglycerols of Chylomicrons & VLDL are hydrolyzed by 
Lipoprotein Lipase. Both phospholipids and apo C-II are required as 
cofactors for lipoprotein lipase activity, while apo A-II and apo C-III act as 
inhibitors. Hydrolysis takes place while the lipoproteins are attached to the 
enzyme on the endothelium. Triacylglycerol is hydrolyzed progressively 
through a diacylglycerol to a monoacylglycerol that is finally hydrolyzed to 
free fatty acid plus glycerol. Fatty acids originating from chylomicron 
triacylglycerol are delivered mainly to adipose tissue, heart, and muscle 
(80%), while about 20% goes to the liver. Reaction with lipoprotein lipase 
results in the loss of approximately 90% of the triacylglycerol of 
chylomicrons and in the loss of apo C (which returns to HDL)but not apo E, 
which is retained. The resulting chylomicron remnant is about half the 
diameter of the parent chylomicron  and is relatively enriched in cholesterol 
and cholesteryl esters because of the loss of triacylglycerol . Similar 
changes occur to VLDL, with the formation of VLDL remnants or IDL 
(intermediate-density lipoprotein). 
                 Chylomicron remnants are taken up by the liver by receptor 
mediated endocytosis, and the cholesteryl esters and triacylglycerols are 
hydrolyzed and metabolized. Uptake is mediated by a  receptor specific for 
apo E and both the LDL (apo B-100,apo E) receptor and the  LRP (LDL 
receptor-related protein) are believed to take part. 
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 LOW DENSITY LIPOPROTEINS 
             VLDL is the precursor of IDL, which is then converted to LDL. 
Only one molecule of apo B-100 is present in each of these lipoprotein 
particles, and this is conserved during the transformations. Thus, each LDL 
particle is derived from only one VLDL particle. Two possible fates await 
IDL. It can be taken up by the liver directly via the LDL (apo B-100, E) 
receptor, or it is converted to LDL. In humans, a relatively large proportion 
forms LDL, accounting for the increased concentrations of LDL in humans 
compared with many other mammals. The liver and many extrahepatic 
tissues express the LDL (B-100, E) receptor. It is so designated because it is 
specific for apo B-100 but not B-48, which lacks the carboxyl terminal 
domain of B-100 containing the LDL receptor ligand, and it also takes up 
lipoproteins rich in apo E. This receptor is defective in familial 
hypercholesterolemia. Approximately 30% of LDL is degraded in 
extrahepatic tissues and 70% in the liver. A positive correlation exists 
between the incidence of coronary atherosclerosis and the plasma 
concentration of LDL cholesterol. 
HIGH DENSITY LIPOPROTEIN 
           HDL is synthesized and secreted from both liver and intestine . 
However, apo C and apo E are synthesized in the liver and transferred from 
liver HDL to intestinal HDL when the latter enters the plasma. A major 
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function of HDL is to act as a repository for the apo C and apo E required in 
the metabolism of chylomicrons and VLDL. Nascent HDL consists of 
discoid phospholipid  bilayers containing apo A and free cholesterol.  LCAT 
and the LCAT activator apo A-I bind to the disk, and the surface 
phospholipid and free cholesterol are converted into cholesteryl esters and 
lysolecithin. The nonpolar cholesteryl esters move into the hydrophobic 
interior of the bilayer, whereas lysolecithin is transferred to plasma albumin. 
Thus, a nonpolar core is generated, forming a spherical, pseudomicellar 
HDL covered by a surface film of polar lipids and apolipoproteins. In this 
way, the LCAT system is involved in the removal of excess unesterified 
cholesterol from lipoproteins and tissues. The class B scavenger receptor B1 
(SR-B1) has recently been identified as an  HDL receptor in the liver and in 
steroidogenic tissues. HDL binds to the receptor via apo A-I and  cholesteryl 
ester is selectively delivered to the cells, but the particle itself, including apo 
A-I, is not taken up. The transport of cholesterol from the tissues to the liver 
is known as  reverse cholesterol transport and is mediated by a HDL cycle . 
The smaller HDL3 accepts cholesterol from the tissues via the ATP-binding 
cassette transporter-1 (ABC-1). ABC-1 is a member of a family of 
transporter proteins that couple the hydrolysis of ATP to the binding of a 
substrate, enabling it to be transported across the membrane. After being 
accepted by HDL3, the cholesterol is then esterified by LCAT, increasing 
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the size of the particles to form the less dense HDL2. The cycle is 
completed by the re-formation of HDL3, either after selective delivery of 
cholesteryl ester to the liver via the SR-B1 or by hydrolysis of HDL2 
phospholipid and triacylglycerol by hepatic lipase. In addition, free apo A-I 
is released by these processes and forms  pre-HDL after associating with a 
minimum amount of phospholipid and cholesterol. Preβ-HDL is the most 
potent form of HDL in inducing cholesterol efflux from the tissues to form 
discoidal HDL. Surplus apo A-I is destroyed in the kidney.  
          
                        
 
 
 
 
 
 
 
                                  Metabolic fate of chylomicrons.(2) 
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             Metabolic fate of very low density lipoproteins (VLDL) and 
production of low-densit lipoproteins (LDL).(2) 
                 
APOLIPOPROTEIN 
               The protein moiety of a lipoprotein is known as an  apo-lipoprotein 
or apoprotein, constituting nearly 70% of some HDL and as little as 1% of 
chylomicrons. Some apolipoproteins are integral and cannot be removed, 
whereas others are free to transfer to other lipoproteins. 
             One or more apolipoproteins (proteins or polypeptides) are present 
in each lipoprotein. The major apolipoproteins of HDL (α-lipoprotein) are 
designated A. The main apolipoprotein of LDL (β-lipoprotein) is 
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apolipoprotein B (B-100) and is found also in VLDL. Chylomicrons contain 
a truncated form of apoB (B-48) that is synthesized in the intestine, while  
B-100 is synthesized in the liver. Apo B-100 is one of the longest single 
polypeptide chains known, having4536 amino acids and a molecular mass 
of 550,000 Da. Apo B-48 (48% of B-100) is formed from the same mRNA 
as apo B-100 after the introduction of a stop signal by an RNA editing 
enzyme. Apo C-I, C-II, and C-III are smaller polypeptides (molecular mass 
7000–9000 Da) freely transferable between several different lipoproteins. 
Apo E is found in VLDL, HDL, chylomicrons, and chylomicron remnants; 
it accounts for 5–10% of total VLDL apolipoproteins in normal subjects. 
  Apolipoproteins carry out several roles: 
(1) they can form part of the structure of the lipoprotein, eg, apo B; 
(2) they are enzyme cofactors, eg, C-II for lipoprotein lipase, A-I for 
lecithin:cholesterol  acyltransferase, or enzyme inhibitors, eg, apo A-II and 
apo C-III for lipoprotein lipase, apo C-I for cholesteryl ester transfer 
protein;  
(3) they act as ligands for interaction with lipoprotein receptors in tissues, 
eg, apo B-100 and apo E for the LDL receptor, apo E for the LDL receptor-
related protein (LRP), which has been identified as the remnant receptor, 
and apo A-I for the HDL receptor. The functions of apo A-IV and apo D, 
however, are not yet clearly defined. 
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SUMMARY OF LIPOPROTEIN METABOLISM  
   Lipids are derived from food (exogenous) or are synthesised in the 
body (endogenous). 
Transport of Dietary Lipids (Exogenous Pathway) 
The exogenous pathway of lipoprotein metabolism permits efficient 
transport of dietary lipids. Dietary triglycerides are hydrolyzed by lipases 
within the intestinal lumen and emulsified with bile acids to form micelles. 
Dietary cholesterol, fatty acids, and fat-soluble vitamins are absorbed in the 
proximal small intestine. Cholesterol and retinol are esterified (by the 
addition of a fatty acid) in the enterocyte to form cholesteryl esters and 
retinyl esters, respectively. Longer-chain fatty acids (>12 carbons) are 
incorporated into triglycerides and packaged with apoB-48, cholesteryl 
esters, retinyl esters, phospholipids, and cholesterol to form chylomicrons. 
Nascent chylomicrons are secreted into the intestinal lymph and delivered 
via the thoracic duct directly to the systemic circulation, where they are 
extensively processed by peripheral tissues before reaching the liver. The 
particles encounter lipoprotein lipase (LPL), which is anchored to a 
glycosylphosphatidylinositol-anchored protein, (GPIHBP1), that is attached 
to the endothelial surfaces of capillaries in adipose tissue, heart, and skeletal 
muscle . The triglycerides of chylomicrons are hydrolyzed by LPL, and free 
fatty acids are released. ApoC-II, which is transferred to circulating 
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chylomicrons from HDL, acts as a required cofactor for LPL in this 
reaction. The released free fatty acids are taken up by adjacent myocytes or 
adipocytes and either oxidized to generate energy or reesterified and stored 
as triglyceride. Some of the released free fatty acids bind to albumin before 
entering cells and are transported to other tissues, especially the liver. The 
chylomicron particle progressively shrinks in size as the hydrophobic core is 
hydrolyzed and the hydrophilic lipids (cholesterol and phospholipids) and 
apolipoproteins on the particle surface are transferred to HDL, creating 
chylomicron remnants. Chylomicron remnants are rapidly removed from the 
circulation by the liver through a process that requires apoE as a ligand for 
receptors in the liver. Consequently, few, if any, chylomicrons or 
chylomicron remnants are present in the blood after a 12-hour fast, except in 
patients with disorders of chylomicron metabolism. 
Transport of Hepatic Lipids (Endogenous Pathway) 
The endogenous pathway of lipoprotein metabolism refers to the 
secretion of apoB-containing lipoproteins from the liver and the metabolism 
of these triglyceride-rich particles in peripheral tissues . VLDL particles 
resemble chylomicrons in protein composition but contain apoB-100 rather 
than apoB-48 and have a higher ratio of cholesterol to triglyceride . The 
triglycerides of VLDL are derived predominantly from the esterification of 
long-chain fatty acids in the liver. The packaging of hepatic triglycerides 
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with the other major components of the nascent VLDL particle (apoB-100, 
cholesteryl esters, phospholipids, and vitamin E) requires the action of the 
enzyme microsomal triglyceride transfer protein (MTP). After secretion into 
the plasma, VLDL acquires multiple copies of apoE and apolipoproteins of 
the C series by transfer from HDL. As with chylomicrons, the triglycerides 
of VLDL are hydrolyzed by LPL, especially in muscle, heart, and adipose 
tissue. After the VLDL remnants dissociate from LPL, they are referred to 
as IDLs, which contain roughly similar amounts of cholesterol and 
triglyceride. The liver removes approximately 40–60% of IDL by LDL 
receptor–mediated endocytosis via binding to apoE. The remainder of IDL 
is remodeled by hepatic lipase (HL) to form LDL. During this process, most 
of the triglyceride in the particle hydrolyzed, and all apolipoproteins except 
apoB-100 are transferred to other lipoproteins. The cholesterol in LDL 
accounts for more than one-half of the plasma cholesterol in most 
individuals. Approximately 70% of circulating LDL is cleared by LDL 
receptor–mediated endocytosis in the liver. Lipoprotein(a) [Lp(a)] is a 
lipoprotein similar to LDL in lipid and protein composition, but it contains 
an additional protein called apolipoprotein(a) [apo(a)]. Apo(a) is 
synthesized in the liver and attached to apoB-100 by a disulfide linkage. The 
major site of clearance of Lp(a) is the liver, but the uptake pathway is not 
known. 
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CHRONIC KIDNEY DISEASE(CKD) 
         CKD is defined according to the presence ,for atleast 3 months ,of 
either of the following :  
1. Structural or functional abnormalities of the kidney that can lead to 
kidney failure 
2. GFR <60 ml /min/1.73m2 
STAGES OF CKD 
              The definitions of Stages 1–5 CKD are based on measured or 
estimated GFR , where the GFR is estimated from the serum creatinine using 
an established formula, as described in the KDOQI CKD Guidelines. 
Stage 1 CKD is defined by estimated GFR 90 mL/ min/1.73 m2, with 
evidence of kidney damage (as defined above). 
Stage 2 CKD is defined as evidence of kidney damage with mildly decreased 
GFR of 60–89 mL/min/1.73 m2.  
Stage 3 CKD: The level of estimated GFR  is 30-59 Ml/min/1.73 m2. 
Stage 4 CKD : The level of estimated GFR is 15 -29 mL/min/1.73 m2 . 
Stage 5 CKD  is defined as GFR <15 mL/min/1.73 m2, or the clinical 
indication for kidney replacement therapy with maintenance 
hemodialysis, peritoneal dialysis, or transplantation. 
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Dyslipidemia Associated with Chronic Kidney Disease 
   CKD is characterized by specific metabolic abnormalities of plasma 
lipoproteins . These abnormalities involve all lipoprotein classes and shows 
variations depending on the degree of renal impairment, the etiology of 
primary disease, the presence of nephrotic syndrome (NS) and the method 
of dialysis [hemodialysis (HD) or peritoneal dialysis (PD)] for patients 
undergoing renal replacement therapy. In patients with CKD, uremia 
related, non -traditional risk factors, such as, inflammation, oxidative stress, 
anemia, malnutrition, vascular calcification (due to alterations in calcium 
and phosphorus metabolism) and endothelial dysfunction have been pro-
posed to play a central role. 
PROTEINURIA 
             Hyperlipidemia of the nephrotic syndrome is clinically obvious. 
There is growing evidence that non-nephrotic proteinuria also affects the 
physiology of lipoproteins. Several studies have shown an association 
between microalbuminuria and dyslipidemia, as well as with other 
components of metabolic syndrome.  In fact, patients with diabetes mellitus 
or hypertension with macroalbuminuria or microalbuminuria have a higher 
rate of dyslipidemia than those with normoalbuminuria. Since CKD is often 
associated with non-nephrotic proteinuria, this could be a mediator of 
uremic dyslipidemia. 
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ALTERATIONS OF TRIGLYCERIDE - RICH LIPOPROTEIN 
METABOLISM IN CKD 
          Hypertriglyceridemia is one of the most common quantitative lipid 
abnormalities in patients with CKD [10,11]. The concentrations of 
triglyceride-rich lipoproteins [very low density lipoprotein (VLDL), 
chylomicrons, and their remnants] start to increase in early stages of CKD 
and show the highest values in NS and in dialysis patients, especially those 
who are treated with PD. 
           Several studies have shown that patients with impaired renal function 
exhibit increased concentrations of triglycerides even though serum 
creatinine levels are within normal limits [12,13] . Also, individuals with 
CKD usually display abnormal increases in serum triglyceride levels after a 
fat meal (postprandial lipemia). The predominant mechanism responsible 
for increased concentration of triglyceride-rich lipoproteins in predialysis 
patients is one of delayed catabolism. The reduced catabolic rate is likely 
due to diminished lipoprotein lipase activity as a consequence of the 
downregulation of the enzyme gene and the presence of lipase inhibitors . 
Apolipoprotein C-III is a potent inhibitor of lipoprotein lipase whereas 
apolipoprotein C-II is an activator of the same enzyme. A decrease in 
apolipo-protein C-II/C-III ratio due to adisproportionate increase in plasma 
apolipoprotein C-III is a possible cause of lipoprotein lipase inactivation in 
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uremia [14,15]. It was also suggested that secondary hyperparathyroidism is 
involved in the impaired catabolism of triglyceride-rich lipoproteins, 
provided an additional mechanism by which CKD may raise plasma 
triglyceride concentration. Except of the low catabolic rate, the increased 
hepatic production of triglyceride-rich lipoproteins may also play a 
contributory role in the pathogenesis of dyslipidemia in renal disease. It is 
well known that CKD causes insulin resistance which can, in turn, promote 
hepatic VLDL production. Thus, it could be hypothesized that the insulin 
resistance driven overproduction of VLDL may significantly contribute to 
the development of hypertiglyceridemia in patients with CKD.[16] 
ALTERATIONS IN LOW DENSITY LIPOPROTEIN (LDL) 
METABOLISM IN CKD 
           Chronic kidney disease in the absence of heavy proteinuria does not 
significantly affect gene expressions of either hydroxyl-3-methylglutaryl-
CoA reductase (HMG-CoA reductase) which is the rate-limiting enzyme  
for cholesterol biosynthesis, or that of cholesterol 7a-hydroxylase which is 
the rate-limiting enzyme for cholesterol catabolism and conversion to bile 
acids . Also, LDL receptor-mediated cholesterol uptake plays an important 
role in cholesterol homeostasis. CKD in the absence of heavy proteinuria or 
significant glomerulosclerosis does not alter hepatic LDL receptor gene 
expression [17]. 
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          Chronic kidney disease  patients, with or without heavy proteinuria, 
display important qualitative alterations in LDL metabolism. The proportion 
of small dense LDL particles, which is considered to be highly atherogenic, 
is increased [18,19]. Small dense LDL is a subtype of LDL that has high 
propensity to penetrate the vessel wall, becomes oxidized and triggers the 
atherosclerotic process. 
HIGH DENSITY LIPOPROTEIN (HDL) AND CKD 
             Patients with CKD have, generally, reduced plasma HDL-
cholesterol levels compared to individuals with normal renal function 
[10,20]. This can be attributed to several mechanisms. Thus, patients with 
impaired renal function usually exhibit decreased levels of apolipoproteins 
AI and AII (the main protein constituents of HDL) , diminished activity of 
LCAT (the enzyme responsible for the esterification of free cholesterol in 
HDL particles) [21,22], as well as increased activity of cholesteryl ester 
transfer protein (CETP)  that facilitates the transfer of cholesterol esters 
from HDL to triglyceride-rich lipoproteins thus reducing the serum 
concentrations of  HDL-cholesterol. In addition to their reduced efficiency 
as cholesterol acceptors, HDL particles from individuals with impaired renal 
function have less effective antioxidative and anti-inflammatory function. 
This impairment can, at least in part, be attributed to the reduction in the 
activities of HDL-associated enzymes, such as paraoxonase (an enzyme that 
inhibits the LDL oxidation).[23] 
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LIPOPROTEIN (a) (LP(a)) AND CKD 
       Lp(a) is a lipoprotein similar to LDL in lipid and protein composition, 
but additionally contains apo(a), which is synthesized in the liver and is 
linked to apo-B-100 by a disulfide bridge. This lipoprotein has high 
homology with plasminogen,   interfering with fibrinolysis, and also binds 
to macrophages, promoting the formation of foam cells. Plasma 
concentrations of Lp(a) are strongly genetically determined by the apo(a) 
gene. Individuals with apo(a) isoforms of high molecular weight usually 
have low mean Lp(a) concentrations, whereas those with isoforms of low 
molecular weight usually exhibit more elevated plasma concentrations of 
Lp(a).[24,25] 
             In addition to the genetic influence, Lp(a) concentrations are also 
affected by the GFR in renal disease.  These concentrations are increased in 
CKD and in nephritic syndrome. In the first case, this increase appears to 
result from decreased catabolism, while in the second, it results from 
increased synthesis. 
Summary of lipoprotein profile abnormality 
1. Increase in Total Triglycerides. 
2. Increase in VLDL and LDL, HDL triglycerides 
3. Slight increase of total cholesterol. 
4. Decrease in HDL Cholesterol 
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Summary of apolipoprotein profile abnormality 
1. Decreased Apo A-I, Apo A-II 
2. Increased Apo C-III 
3. Decreased Apo –E  
4. Normal or increased levels of Apo B 
ALTERATIONS OF TRIGLYCERIDE-RICH LIPO-PROTEIN 
METABOLISM  IN  DIALYSIS PATIENTS WITH CKD 
           The initiation of renal replacement therapy, as well as the choice of 
dialysis modality, may also influence the levels of triglyceride-rich 
lipoproteins in ESRD patients [11]. The pathophysiological mechanisms 
responsible for these alterations seem to be generally similar with those 
described in predialysis patients with CKD. However, factors related to the 
procedure of renal replacement therapy seem to contribute to the increased 
levels of triglycerides observed in this patient group. In HD patients the 
repeated use of low-molecular heparins for anticoagulation may lead to a 
defective catabolism of triglyceride-rich lipoproteins as heparin releases 
lipoprotein lipase from the endothelia surface and thus its chronic use may 
result in lipoprotein lipase depletion. 
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          In addition, controversy exists as to whether low-molecular weight 
heparins have a more favourable effect on the lipid profile of HD patients 
compared to standard unfractionated heparin [26, 27]. Also, studies on  
the influence of the type of membrane used in HD yielded conflicting 
results. It has been shown that the use of high-flux polysulfone or cellulose 
triacetate membranes is accompanied by a significant reduction in serum 
triglyceride. This improvement could, at least in part, be attributed to an in-
crease in the apolipoprotein C-II/CIII ratio which increases the activity of 
lipoprotein lipase and facilitates the intravascular lipolysis of triglyceride-
rich lipoproteins [28]. 
ALTERATIONS IN LOW DENSITY LIPOPROTEIN (LDL) 
METABOLISM IN  DIALYSIS PATIENTS WITH CKD 
        In HD patients the serum lipid concentrations resemble those of 
predialysis patients with CKD, which means that total and LDL cholesterol 
levels are generally normal, whereas the subfractionation of apolipoprotein 
B-containing lipoproteins usually reveals a predominance of small dense 
particles [29]. On the other hand, CAPD patients exhibit a more atherogenic 
lipid profile that is characterized by higher total and LDL cholesterol values 
and increased concentrations of small dense LDL and apolipoprotein B [11]. 
A number of possible factors associated with the PD treatment may explain 
those alterations in lipoprotein metabolism. It is known that CAPD 
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(continuous ambulatory peritoneal dialysis) patients lose substantial 
amounts of plasma proteins into the peritoneal dialysate. This protein loss 
may, in turn, stimulate the hepatic synthesis of albumin and other liver-
derived proteins, including cholesterol enriched lipoproteins [30]. It should 
be also mentioned that, in CAPD patients, substantial amounts of apol-
ipoproteins and intact lipoproteins are lost via the peritoneal cavity. 
However the pathophysiological significance of these loses remains unclear.  
 
HIGH DENSITY LIPOPROTEIN (HDL) METABOLISM IN  
DIALYSIS PATIENTS WITH CKD 
             Hemodialysis   procedure may also have a contributory role in the 
reduced HDL cholesterol levels of dialysis patients. Thus, in dialysis 
patients the type of membrane and dialysate used in HD procedure may 
influence the HDL-cholesterol levels. It has been shown that the use of 
high-flux instead of low flux membranes is associated with an increase in 
apolipoprotein AI and HDL-cholesterol values. [31,32]. In addition, the type 
of dialysate may also significantly affect the serum levels of lipoproteins in 
HD patients. Indeed, it has been shown that the use of bicarbonate dialysate 
may result in higher HDL-cholesterol concentrations than the use of acetate 
dialysate [33]. 
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LIPID PROFILE CHANGES IN DIFFERENT GROUPS:(4) 
 
 
                   
HYPERLIPIDEMIA   AFTER   KIDNEY   TRANSPLANTATION 
          Hyperlipidemia is common after renal transplantation. The 
pathogenesis of hyperlipidemia in renal transplant patients is poorly 
understood. Several possible causes include immunosuppressive therapy, 
genetic predisposition, age, gender, body-weight gain, renal function,  
proteinuria, diabetes, and antihypertensive drugs. However, the relative 
contribution of these factors in the genesis of post-transplant  
hyperlipidemia is unclear. Post-transplant hyperlipidemia is related to 
immunosuppressive therapy in a dose-dependent fashion [34]. Moreover, 
the association between immunosuppressive therapy and hyperlipidemia has 
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generally been observed early after transplantation, and it is probable that 
the persistent lipid abnormalities in the late post-transplant period are also 
the result of factors other than immunosuppressive therapy. 
            After trans-plantation and renal function recovery, lipid disturbances 
usually persist but show a different profile due to the various effects of 
immunosuppressive drugs,  such as calcineurin inhibitors (cyclosporine and 
tacrolimus), antiproliferative drugs (mycophenolate mofetil and 
azathioprine), mammalian target of rapamycin inhibitors (sirolimus and 
everolimus), and corticosteroids[36,37]. The most frequent alterations in the 
lipid profile of renal transplant recipients are elevated total cholesterol, LDL 
cholesterol and trigly-ceride concentrations, and decreased HDL cholesterol 
concentrations, although an increase in HDL cholesterol is frequently 
observed in patients treated with corticosteroids, such as prednisone and 
deflazacort. 
Post-Transplant Triglyceride-Rich Lipoprotein Metabolism 
             The altered metabolism of triglyceride-rich lipoproteins is probably 
the result of either increased hepatic secretion of very-low-density 
lipoproteins (VLDL), or decreased peripheral triglyceride-rich lipoprotein 
removal, or both [35]. Cattran et al. Studied triglyceride turnover 
sequentially for up to 3 years post-transplantation and demonstrated that 
overproduction of triglycerides was the predominant defect.  
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 Hyperinsulinemia secondary to insulin-resistance might stimulate 
hepatic triglyceride-rich lipoprotein production. Indeed, hyperinsulinemia 
has been positively, but inconsistently, correlated to triglyceride 
concentrations in renal transplant patients. Corticosteroid treatment is 
probably the primary cause of insulin-resistance (36). Corticosteroids could 
increase the rate-limiting enzymes of lipogenesis, acetyl-C0A carboxylase, 
and free fatty acid synthetase.  
            A decrease in the catabolism of triglyceride-rich lipoproteins in renal 
transplant patients is evidenced by a decrease in VLDL turnover rate, a 
decrease in the fractional clearance rate of intra lipid , and a decrease in the 
postprandial triglyceride clearance rate . Lipoprotein lipase (LPL) and 
hepatic triglyceride lipase (HTGL) are responsible for the catabolism of 
triglyceride-rich lipoproteins. The function of LPL and HTGL, measured by 
total post-heparin lipolytic activity, have been reported to be normal or 
reduced. [37,38]  
 Post-Transplant Cholesterol-Rich Lipoprotein Metabolism 
          Increased synthesis of VLDL with normal conversion of VLDL to 
LDL could cause increased levels of LDL [39]. However, whether the 
conversion of VLDL to LDL is normal in renal transplantation is unclear. 
Triglyceride enrichment of LDL has been documented in corticosteroid 
treated patients, and triglyceride-enriched LDL may be less accessible for 
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receptor uptake and degradation . As previously mentioned, corticosteroids 
and cyclosporine could theoretically interfere with LDL-receptor activity 
[40,41]. Moreover, the decrease of bile-acid synthesis caused by 
cyclosporine, as demonstrated In vitro, could cause downregulation of 
hepatic LDL-receptor expression by feedback mechanisms[42,43]. It should 
be noted that renal transplant patients have several factors (including insulin 
resistance, renal failure, decreased apo C-Il/C-Ill ratio, and beta-blocker use) 
that could theoretically reduce the synthesis and/or the activity of these 
lipases. Moreover, the abnormal lipid and apoprotein content of triglyceride-
rich lipoproteins could theoretically inhibit their catabolism, and triglyceride 
enrichment of VLDL has been documented in renal transplant patients 
[40,41] . Finally, because the LDL receptor also recognizes VLDL, reduced 
hepatic LDL-receptor number and/or function could lead to the 
accumulation of triglyceride-rich lipoproteins. Corticosteroids have been 
shown to inhibit LDL-receptor activity . Cyclosporine could theoretically 
interfere with LDL receptors, leading to increased LDL levels. [44,45,46] 
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Schematic representation of triglycerides and cholesterol metabolism.[6] 
 
 
Effect of immunosuppressive drugs on lipid profile[4] : 
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Summary of Lipid Profile Changes after Transplantation  
1.   Increase in total cholesterol with increase in VLDL, and LDL  
 cholesterol.  
2.  Increase in Triglycerides.  
3.  Decrease in HDL cholesterol 
DYSLIPIDEMIA IN INDIANS 
Table : 3 
Optimum level of Risk factors for Asian Indians: 
Risk factors Male Female 
Cholesterol (mg/dl) <150 <150 
LDL(mg/dl) <100 <100 
HDL (mg/dl) >40 >50 
Triglyceride (mg/dl) <150 <150 
Lp(a) (mg/dl) <20 <20 
 
TREATMENT OF ADULTS WITH DYSLIPIDEMIAS 
GUIDELINE 4 
►  For adults with Stage 5 CKD and fasting triglycerides >500 mg/dL 
(>5.65 mmol/L) that cannot be corrected by removing an  underlying 
cause, treatment with therapeutic lifestyle changes (TLC) and a 
triglyceride lowering agent should be considered.  
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►  For adults with Stage 5 CKD and LDL >100 mg/dL (>2.59 mmol/L), 
treatment should be considered to reduce LDL to <100 mg/dL (<2.59 
mmol/L).  
►  For adults with Stage 5 CKD and LDL <100 mg/dL (<2.59  mmol/L), 
fasting triglycerides  >200  mg/dL (>2.26  mmol/L), and non-HDL 
cholesterol (total cholesterol minus HDL) >130 mg/dL (>3.36 
mmol/L), treatment should be considered to reduce non-HDL 
cholesterol to <130mg/dL (<3.36 mmol/L). 
Table : 4 
The Management of Dyslipidemias in Adults with  
Chronic Kidney disease  
 
Dyslipidemia Goal Initiate Increase Alternative 
 
TG> 500mg/dl 
 
TG <500mg/dl 
 
TLC 
 
TLC + Fibrate 
or Niacin 
 
Fibrate or Niacin 
LDL  
100 – 129mg/dl 
 
LDL  < 100mg/dl 
 
TLC 
 
TLC + low 
dose Statin 
 
Bile acid seq or 
Niacin 
LDL 
> 130 mg/dl 
 
LDL < 100mg/dl 
 
TLC + low 
dose Statin 
 
TLC + max 
dose Statin 
 
Bile acid seq or 
Niacin 
TG 200mg/dl and 
non HDL 
>130mg/dl 
 
non HDL 
<130mg/dl 
 
TLC + low 
dose Statin 
 
TLC + max 
dose Statin 
 
Fibrate or Niacin 
 
 
TLC – Therapeutic Lifestyle Changes. 
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Therapeutic Lifestyle Changes (TLC) for Adults with Chronic Kidney 
Disease. 
Diet  
Emphasize reduced saturated fat:  
       Saturated fat : <7% of total calories 
       Polyunsaturated fat : up to 10% of total calories  
       Monounsaturated fat : up to 20% of total calories 
       Total fat : 25 %- 35% of total calories  
       Cholestrol : <200 mg per day 
       Carbohydrates : 50%-60% of total calories 
Emphasize components that reduce dyslipidemia: 
       Fiber 20 -30 g /day emphasize 5 -10g/day viscous (soluble ) fiber. 
       Consider plant stanols / sterols 2g/day 
       Improve glycemic control  
Emphasize total calories to attain /maintain standard NHANES body weight 
       Match intake of overall energy (calories) to overall energy needs 
       Body Mass Index 25 -28kg/m2 
       Waist circumference  
               Men <40 inches (102cm) 
               Women <35 inches (102cm) 
               Waist – hip Ratio (Men <1.0; Women <0.8). 
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ROLE OF STATINS 
                Statins inhibit 3-hydroxy-3-methylglutaryl coenzyme A reductase  
and are the most widely studied drug class in the treatment of dyslipidemia 
in ESRD[47]. The renoprotective effect of statins may not be only due to 
lipid reduction, but also to a decrease of renal interstitial inflammation,  
improvement of renal hemodynamics, and a decrease in glomerular 
proteinuria. Statins may also have a beneficial effect on vascular stiffness 
and endothelial function in renal failure. Current recommendations are to 
reduce the statin dose by 50% in dialysis patients, except for atorvastatin 
and pravastatin[48].  In transplant recipients, a lower starting dose of statins 
should be used, particularly with concomitant use of cyclosporine. 
Nicotinic acid 
               Nicotinic acid is highly effective in increasing HDL  by decreasing 
cholesterol transfer from HDL to VLDL and also by decreasing HDL 
clearance  and is the only available drug to substantially lower plasma 
Lp(a). This drug also reduces VLDL secretion by the liver. In the general 
population nicotinic acid has been shown to improve cardiac and 
cerebrovascular prognosis. Studies in CKD are small and of short duration, 
but showed the expected changes in lipid profile. 
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Fibrates 
      Fibrates are PPAR a activators.  Activation of this transcriptional factor 
increases oxidation of fatty acids in the liver, kidney, heart, and skeletal 
muscle and reduces hepatic production of apo-CIII and increases expression 
of LPL, apo-AI, and apo-AII,  as well as increases HDL and lowers total 
cholesterol, triglycerides, and LDL.  Given the early development of 
hypertriglyceridemia in CKD, fibrates would be logical candidates for the 
treatment of dyslipidemia in this disease, but are not often used because of 
the risk of rhabdomyolysis,[49]  worsening of renal function, impairment of 
liver function, and elevation of homocysteine in these patients. The NKF 
guidelines favour the use of gemfibrozil because this drug does not requires 
dose adjustment for the decrease in GFR and its pharmacokinetics are not 
altered in this context. These guidelines discourage the use of fibrates in 
patients with GFR< 15 mL/min.[24] 
Ezetimibe 
         Ezetimibe has low interaction with other drugs and can therefore be 
used in conjunction with statins or other lipid-lowering drugs. 
Coadministration of cholestyramine decreases its bioavailability, while the 
concomitant use of gemfibrozil and fenofibrate slightly increases its 
availability. This agent can reduce cyclosporine levels.[47] 
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MATERIALS AND METHOD OF STUDY 
 The study of lipid profile in patients of chronic kidney disease was  
undertaken in The Department of Nephrology, Madurai medical college, 
Madurai.  
SUBJECTS FOR THE STUDY  
•  The study group constituted patients of   
a)  Chronic kidney disease on conservative management  
b)  Chronic kidney disease on regular hemodialysis.  
c)  Post Renal Transplantation with normal renal function.  
•   The control group constituted  twenty healthy adults – 10 males and  
10 females of different age groups  whose ages compared well with  
that of   study group.  
SELECTION OF CASES    
STUDY GROUP   
a.   Patients with chronic kidney disease on conservative management for 
a period of at least 6 months comprising of 10 males and 10 females  
within the age group of 20-50 years  with none of them having 
diabetes were taken up.    
b.   Patients presenting with end stage renal failure on maintenance 
 hemodialysis for period of 3 months comprising of 11 males and 9  
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females, all falling within the age group of 20 years to 50 years were 
taken up and none of them had Diabetes . 
c.   Post transplant patients with normal renal functions comprising of 10 
males and 10 females within the age group of 20- 50 years and none 
of them had Diabetes.  
CONTROL GROUP  
 This group consisted of 10 males and 10 females whose age group  
compared well with that of the study  group. It was ascertained that none of  
them had hypertension, diabetes mellitus, renal or liver disease or any other  
metabolic disorder.  
METHOD OF STUDY  
Estimation of lipid profile  
The various parameters analysed  were :  
►  Serum total cholesterol  (TC)  
►  Serum high density lipoprotein cholesterol (HDL)  
►  Serum low density lipoprotein cholesterol (LDL)  
►  Serum triglycerides  (TG)  
►  Ratio of serum total cholesterol to high density lipoprotein  
      cholesterol (TC/HDL).  
 Samples were collected after a 12 hour fast to avoid post prandial 
rise in serum triglyceride level. 
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               Analysis of total cholesterol, triglycerides and HDL was done by 
use of an autoanalyser. Serum LDL cholesterol was calculated by 
Frederickson Friedwald’s formula according to which LDL=total 
cholesterol – (HDL+VLDL). VLDL was calculated as 1/5th of triglycerides. 
LDL= Total Cholesterol –( HDL+ (triglycerides / 5), in mg/dL. The results 
were statistically analysed.(one way ANOVA, ‘t’ test) 
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RESULTS 
Table – 1 
Values of Total cholesterol in different groups 
Total 
cholesterol  
mg/dl 
Conservative
N=20 
Post 
Transplant
N=20 
Haemodialysis 
N=20 
Control
N=20 
< 200 20 14 18 20 
200 - 239 0 6 2 0 
> 240 0 0 0 0 
 
Table – 2 
Values of Triglycerides in different groups 
 
 
Triglycerides 
mg/dl 
Conservative
N=20 
Post 
Transplant
N=20 
 
Haemodialysis 
N=20 
Control
N=20 
< 150 11 0 1 19 
150 - 199 9 8 19 1 
> 200 0 12 0 0 
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Table – 3 
Values of HDL in different groups 
HDL 
mg/dl 
Conservative
N=20 
Post 
Transplant 
N=20 
 
Haemodialysis 
N=20 
Control
N=20 
< 40 18 13 17 0 
40 - 59 2 7 3 20 
> 60 0 0 0 0 
 
 
Table – 4 
Values of LDL in different groups 
LDL 
mg/dl 
Conservative
N=20 
Post 
Transplant
N=20 
 
Haemodialysis 
N=20 
Control
N=20 
< 100 18 6 18 20 
100 - 129 2 11 2 0 
> 130 0 3 0 0 
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Table – 5 
Values of total cholesterol / HDL ratio in different groups 
Total 
cholesterol/HDL 
Conservative
N=20 
Post 
Transplant
N=20 
Haemodialysis 
N=20 
Control
N=20 
<4 2 0 6 20 
4 - 6 18 18 14 0 
> 6 0 2 0 0 
 
Table – 6 
Serum Total cholesterol in Different groups with their 
comparison 
Group No.of cases Mean P value Significance
Conservative 20 158.45 < 0.001 Significant 
Post transplant 20 190.15 < 0.001 Significant 
Haemodialysis 20 147.3 < 0.001 Significant 
Control 20 126.6   
   
Table 6 shows that the mean total cholesterol of the post transplant 
group is significantly high compared to other groups. 
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Table – 7 
Serum triglyceride in Different groups with their comparison 
Group No.of cases Mean P value Significance
Conservative 20 153.55 < 0.001 Significant 
Post transplant 20 208.25 < 0.001 Significant 
Haemodialysis 20 161.8 < 0.001 Significant 
Control 20 120.25   
 
Table 7 shows that the serum triglyceride levels is significantly high 
in all the groups when compared with control group. 
Table – 8 
Serum LDL in Different groups with their comparison 
Group No.of cases Mean P value Significance
Conservative 20 92.35 < 0.001 Significant 
Post transplant 20 110.95 < 0.001 Significant 
Haemodialysis 20 78.8 < 0.001 Significant 
Control 20 58.9   
 
Table 8  shows that the mean LDL cholesterol of the post transplant 
significantly high in comparison with the other groups. 
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Table – 9 
Serum HDL in Different groups with their comparison 
Group No.of cases Mean P value Significance
Conservative 20 36.3 < 0.001 Significant 
Post transplant 20 37.9 < 0.001 Significant 
Haemodialysis 20 36.15 < 0.001 Significant 
Control 20 43.7   
 
Table 9 shows the mean HDL cholesterol is significantly low in all 
the three gropus. 
Table – 10 
Total cholesterol / HDL ratio  
in Different groups with their comparison 
Group No.of cases Mean P value Significance
Conservative 20 4.3 < 0.001 Significant 
Post transplant 20 5.02 < 0.001 Significant 
Haemodialysis 20 3.9 < 0.001 Significant 
Control 20 2.9   
 
Table 10 shows  the ratio of total cholesterol /HDL in post transplant 
group is significantly high when compared to other groups. 
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Table – 11 
Conservative group  
Conservative Male Female P value  Significance 
TCL 160 156 0.205 Not Significant 
TGL 163 144 <0.001  Significant 
HDL 36 36 0.654 Not Significant 
LDL 92 92 0.918 Not Significant 
Tchl/HDL 4.4 4.3 0.308 Not Significant 
 
Table 11 shows except for triglycerides there is no significant 
difference noticed on comparison of lipid profile values between  male and 
female in conservative groups.  
Table – 12 
Post transplant group  
Post transplant Male Female P value  Significance 
TCL 186 193 0.457 Not Significant 
TGL 210 206 0.836 Not Significant 
HDL 37.9 37.9 0.968 Not Significant 
LDL 106.9 115 0.335 Not Significant 
Tchl/HDL 4.9 5.1 0.477 Not Significant 
Table 12 shows comparison of lipid profile between male and females 
in post transplant group showed no significant difference. 
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Table – 13 
Haemodialysis group  
Haemodialysis Male Female P value  Significance 
TCL 142 142        0.912 Not Significant 
TGL 157 162 0.762 Not Significant 
HDL 36 36.3 0.938 Not Significant 
LDL 75 73.4 0.779 Not Significant 
Tchl/HDL 3.9 3.9 0.797 Not Significant 
 
Table 13 shows no significant difference in lipid profile values 
noticed between male and females in hemodialysis group. 
Table – 14 
Control group  
Control Male Female P value  Significance 
TCL 125 127.7 0.586 Not Significant 
TGL 114.8 125.7 0.081 Not Significant 
HDL 44.2 43.4 0.456 Not Significant 
LDL 58.9 58.9 1.00 Not Significant 
Tchl/HDL 2.8 2.9 0.314 Not Significant 
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SUMMARY OF THE OBSERVATION 
The lipid profile study of chronic kidney disease patients on 
conservative management, on regular haemodialysis and post 
transplantation showed the following changes. 
1.   SERUM TOTAL CHOLESTEROL 
The total cholesterol levels were normal in all the 20 (100%) patients 
in the conservative management group. The levels were normal in 18(90%) 
and  borderline high in 2(10%) in the haemodialysis (CKD – HD) group . In 
the post transplant group the levels were normal in 14(70%) and  borderline 
high in 6(30%)  patients. 
The mean total cholesterol in the control group was 126.60mg/dl, the 
conservative management group was 158.45mg/dl, CKD – HD group was 
147.3mg/dl and the post transplant group was 190.15mg/dl. The mean 
cholesterol was significantly increased in the post transplant group when 
compared to the other groups. 
2. SERUM TRIGLYCERIDES 
The triglycerides levels were normal in 11 (55%) and borderline high 
in 9(45%) patients in conservative management group.  
The levels were normal in 1(5%) and borderline high in 19(95%) 
patients in the CKD – HD group. In the post transplant group the levels 
were borderline high in 8(40%) and elevated in 12(60%) patients. 
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The mean triglyceride of the control group was 120.25mg/dl, the 
conservative management group was 153.55mg/dl, CKD – HD group was 
161.80mg/dl and the post transplant group was 208.25mg/dl. The mean 
triglycerides level was significantly increased in all study groups when 
compared to controls. 
3. LDL CHOLESTEROL 
The LDL cholesterol levels were normal in 18(90%) and borderline 
high in 2(10%)  patients  in the conservative management group. 
The LDL cholesterol levels were normal (below 100 mg/dl) in 
18(90%) and borderline high in 2(10%) patients in the CKD – HD group. In 
the post transplant group the levels were normal in 6(30%), borderline high 
in 11(55%) and elevated in 3(15%) patients. 
The mean LDL cholesterol of the control group was 58.90mg/dl, the 
conservative management was 92.35mg/dl, the CKD – HD group was 
78.8mg/dl and the post transplant group was 110.95mg/dl. The mean LDL 
cholesterol was significantly increased in all study groups when compared 
to controls, whereas in conservative group and haemodialysis group the 
mean LDL cholesterol was within optimal level (<100mg/dl). 
4. HDL CHOLESTEROL 
The HDL cholesterol levels were decreased in 18 (90%) and normal 
in 2(10%) patients in the conservative management group. The levels were 
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decreased in 17(85%), normal in 3 (15%) patients in CKD – HD group. In 
the post transplant group the levels were decreased in 13(65%) and normal 
in 7(35%) patients. The mean HDL cholesterol of the control group was 
43.7mg/dl, conservative management group was 36.3mg/dl, CKD – HD 
group was 36.15mg/dl and the post transplant group was 37.9mg/dl. HDL 
cholesterol was significantly decreased in all study groups when compared 
to controls. 
5. RATIO OF TOTAL CHOLESTEROL/HDL CHOLESTEROL 
        The total cholesterol/HDL ratio were normal in 2 (10%) and borderline 
high in 18(90%) patients in conservative management group. The levels 
were normal in 6 (30%) and borderline high in 14(70%) patients in the  
CKD – HD group . In the post transplant group the levels were borderline 
high in 18(90%) and elevated in 2(10%) patients. The total cholesterol/HDL 
ratio of control group was 2.9, conservative management group was 4.3, 
CKD – HD group was 3.9 and the post transplant group was 5.02. The TC / 
HDL ratio was significantly increased in all study groups when compared to 
controls. 
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DISCUSSION 
                Chronic kidney disease (CKD) results in profound lipid disorders,  
which stem largely  from dysregulation of high density lipoproteins (HDL) 
and triglyceride-rich lipoprotein  metabolism. Specifically, maturation of 
HDL is impaired and its composition is altered in CKD. In addition, 
clearance of triglyceride-rich lipoproteins and their atherogenic remnants is 
impaired, their composition is altered, and their plasma concentrations are 
elevated in CKD. Impaired maturation of HDL in CKD is primarily due to 
down regulation of lecithin-cholesterol-acyltransferase and, to a lesser 
extent, increased plasma cholesteryl ester transfer protein (CETP). 
Triglyceride enrichment of HDL in CKD is primarily due to hepatic lipase 
deficiency and elevated CETP activity. The CKD induced 
hypertriglyceridemia, abnormal composition, and impaired clearance of  
triglyceride-rich lipoproteins and their remnants are primarily due to down 
regulation  of lipoprotein lipase, hepatic lipase, and the very low density 
lipoprotein receptor, as well as, up regulation of hepatic acyl-CoA 
cholesterol acyltransferase (ACAT). In addition, impaired HDL metabolism 
contributes to the disturbance of triglyceride-rich lipoprotein metabolism. 
These abnormalities are compounded by down regulation of   
apolipoproteins apoA-I, apoA-II and apoC-II in CKD. Together, these 
abnormalities may contribute to the risk of atherosclerotic cardiovascular 
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disease and may adversely affect progression of renal disease and energy 
metabolism in CKD. This study was conducted to determine the lipid profile 
changes in chronic renal failure patients on conservative management, on 
regular hemodialysis and post renal transplant patients with normal renal 
function and to compare them with healthy controls. 
The study population was 60 patients with 20 patients in each group 
and 20 healthy controls. Each group had 10 males and 10 females to 
compare the sex variation. 
               All the persons involved in the study were between 20-50 years. It 
was ensured that none of the control group had diabetes mellitus, 
hypertension, renal, liver or any metabolic disorder. It was also ensured that 
none of the patients in the study group had diabetes. Serum total cholesterol, 
HDL cholesterol, LDL cholesterol , Triglycerides, Total cholesterol /HDL 
cholesterol ratio were measured using an autoanalyser, after a 12 hour fast. 
The results were statistically analysed based on the following guidelines. 
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 ADULT TREAMENT PANEL III (ATP III ) GUIDELINES[50] 
 
DYSLIPIDEMIA                                       LEVEL (mg /dl) 
Total cholesterol 
   Desirable                                                  < 200 
   Borderline high                                         200-239 
   High                                                          > 240 
LDL cholesterol 
   Optimal                                                     < 100 
   Near optimal                                               100-129 
   Borderline                                                   130-159 
   High                                                           > 160 
Triglycerides 
   Normal                                                        < 150 
   Borderline high                                             150 -199 
   High                                                              200-499 
  Very high                                                     > 500 
HDL cholesterol 
Low                                                               < 40 
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Lipid changes in CKD patient on conservative management : reported 
studies  
1.  The characteristic plasma lipid abnormality in CRF patients is 
moderate hypertriglyceridemia - this is due to impaired carbohydrate 
tolerance leading to increased hepatic synthesis of VLDL and 
decreased activity of lipoprotein lipase and hepatic triglyceride lipase 
leading to decreased fractional catabolic rate of triglycerides. 
2.  Decrease in HDL cholesterol level - this is due to the deficiency of 
LCAT which is essential for esterification of cholesterol. LCAT plays 
an important role in HDL mediated cholesterol uptake from the extra 
hepatic tissues and serves as a main determinant of HDL maturation 
and plasma HDL cholesterol level. Decrease in HDL level is also 
contributed by elevation of CETP. 
3.  Normal or slightly increased total cholesterol level. 
4.  Normal or slightly increased LDL cholesterol level. 
Observation on lipid profile changes of CKD patients on conservative 
management showed the following results: 
The mean age of the control group was 41.7 yrs and the conservative 
management group was 39.55 yrs. There was no significant difference in the 
lipid profile between the males and the females in the conservative 
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management group except for triglyceride level which showed significant 
difference. This may be due to different dietary pattern.              
The total cholesterol levels were normal in all the patients in 
conservative group. The mean total cholesterol in the conservative 
management group was 158.45mg/dl and control was 126 mg/dl. This was  
statistically significant. The triglyceride levels were borderline high in 
45%.The mean triglyceride level in the conservative management group was 
153.55mg/dl and was significantly increased when compared to a mean of 
126.6 mg/dl in the control group. 
The LDL levels were normal in 90% and borderline high in 10% and 
HDL was <40mg/dl in 90%.The mean LDL cholesterol in the conservative 
management group was 92.35mg/dl and control was 58.9mg/dl. This 
difference was significant. The mean HDL cholesterol in conservative 
management group was 36.3mg/dl and was significantly decreased when 
compared to the controls. The mean TC/HDL cholesterol ratio in 
conservative management group was 4.31 and was significantly increased 
compared to control. 
The final results revealed a (1) significant decrease in HDL 
cholesterol (2) significant increase in triglyceride levels (3) significant 
increase in TC/HDL cholesterol ratio (3)  significant increase in serum total 
cholesterol and LDL cholesterol when compared to the control group.  
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The significant decrease in HDL could be due to various reasons 
mentioned earlier (decrease in LCAT, hepatic lipase activity, increase in 
ACAT, decrease in apoA-I and apoAII) and the cause for 
hypertriglyceridemia has been mentioned earlier.   
           In a study by Attman PO et al [51] revealed increased VLDL ; 
remnants and intermediate density lipoproteins; prolonged persistence of 
postprandial chylomicrons  and accumulation of noncardioprotective acute 
phase HDL in renal disease patients. Another study by Bagdade, casaretto 
A, Albers J showed the same effects of chronic uremia on lipid profile.[52] 
Lipid changes in post transplant patients – reported studies 
The characteristic pattern noted in earlier studies were 
(1) Increase in total cholesterol with increase in VLDL and LDL cholesterol 
(2) Increase in Triglycerides. 
(3) Decrease in HDL cholesterol 
          In posttransplant patients  different  lipid profile  changes are due to 
the various effects of immunosuppressive drugs,  such as calcineurin 
inhibitors (cyclosporine and tacrolimus), antiproliferative drugs 
(mycophenolate mofetil and azathioprine), mammalian target of rapamycin 
inhibitors (sirolimus and everolimus), and corticosteroids.  
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Observation on lipid profile changes of post transplant patients showed 
the following results 
The mean age of this group was 38.2yrs and there was no significant 
difference in the lipid profile between males and females. 
The total cholesterol levels were borderline high in 30% of the 
patients in this group. The mean total cholesterol in post transplant group 
was 190.15mg/dl and was significantly increased when compared to the 
controls which was 126mg/dl. The triglyceride levels were borderline high 
in 40% and elevated in 60%. The mean triglyceride level in the post 
transplant group was 208.25mg/dl and was significantly increased when 
compared to 120.25mg/dl in the controls. 
The LDL levels were borderline high in 55% and elevated in 15% and 
HDL was decreased in 65% of the cases. The mean LDL cholesterol in the 
post transplant group was 110.95mg/dl and was significantly increased 
when compared to 59mg/dl in the controls. The mean HDL cholesterol in 
the post transplant group was 37.9mg/dl and was significantly decreased 
when compared to the control group which was 43.7mg/dl. The mean 
TC/HDL cholesterol ratio in the post transplant group was 5.02 and was 
significantly increased when compared to 2.9 in the controls. 
The final results revealed a (1) significant increase in serum 
triglycerides (2) significant increase in total cholesterol (3) significant 
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increase in LDL cholesterol (4) significant decrease in HDL cholesterol (5) 
significant increase in total cholesterol/HDL ratio when compared to the 
control group. 
         In a study done by Ziad A.Massy, B.L. Kasiske [55] reported same 
changes of serum lipids include increases in both triglycerides and total 
cholesterol. Another study by Ponticelli C,Barbi GL ,Cantaluppi A et al 
[35]revealed the same lipid disorders in renal transplant recipients. Study 
done by Brown et al revealed that 83-87 % of post transplant patients had 
high total cholesterol,90% had high LDL which correlates with our study. 
Lipid changes in CKD patients on Haemodialysis : Reported studies 
1. Moderate increase in triglyceride levels 
2. Decrease in HDL levels 
3. Normal / slightly elevated total cholesterol, LDL cholesterol 
4. Increased Lp(a) 
5. Increased apoB and apoA-IV and decreased apo A-I 
In addition to factors responsible for renal dyslipoproteinemia the 
other contributing factors in a CKD-HD patient are 
1.  Reduced lipolytic activity following repeated heparinisation. The 
exact reason is not understood but may be due to functional insulin 
deficiency or insulin resistance, and also due to the presence of non 
dialyzable factor of lipolytic enzyme (lipoprotein lipase), in the 
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plasma of CKD-HD patients. The changes are more pronounced with 
the use of conventional heparin than low molecular weight heparin. 
2.  The presence of Acetate in the dialysate which gets converted to long 
chain fatty acids and later to cholesterol in the liver. 
3.  Carnitine deficiency  results  in impaired fatty acid oxidation. 
 
Observation on lipid profile changes of CKD- HD showed the following 
results 
The mean age of the hemodialysis group was 38.95 yrs. There was no 
significant difference in the lipid profile between males and females in this 
group. 
The total cholesterol levels were normal in 90% and elevated in 10% 
of cases. The mean total cholesterol in the CKD – HD group was 
147.3mg/dl and control was 126mg/dl. This difference was  significant. The 
triglyceride levels were normal in 5% and   borderline high  in 95%. The 
mean triglyceride level in the CKD – HD group was 161.8 and was 
significantly increased when compared to the controls. 
The LDL cholesterol levels were normal in all of patients in this 
group. The mean LDL cholesterol in the CKD – HD group was 78.8mg/dl 
and in the control was 58.9mg/dl. This difference was  significant. The HDL 
cholesterol levels were below 40 mg/dl in 85%.The mean HDL cholesterol 
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in the CKD – HD group was 36.15mg/dl and was significantly decreased 
when compared to 43.7mg/dl in the control group. The Total Cholesterol / 
HDL ratio was elevated in 12 (60%) patient. The mean Total 
Cholesterol/HDL cholesterol ratio in CKD – HD group was 3.9 and was 
significantly increased when compared to 2.9 in the control group. 
The final results revealed a  
 (1)  significant decrease in HDL cholesterol 
 (2)  significant increase in triglyceride levels 
 (3)  significant increase in TC/HDLcholesterol ratio  
 (4)   significant changes in serum total cholesterol and LDL 
         In a study by  Deighan CJ, Caslake MJ, McConnel  revealed tha same 
lipid changes in dialysis patients. Shoji T , and Huttunnen JK tested the role 
of heparin in the pathogenesis of HD induced dyslipidemia revealed the 
same changes[53,54]. But According to ATP III guidlines 55.7% would 
require treatment based on LDL >100. 
           From this study it is inferred that dyslipidemias are common in 
chronic renal failure patients and especially more pronounced in transplant 
recipients. 
The  National Kidney Foundation task force on CVD (Cardiovascular 
disease) concluded that the incidence of ACVD is higher in patients with 
CKD compared to the general population. The task force concluded that 
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patients with CKD should be considered to be in the highest risk category, 
ie,a CHD (Coronary heart disease) risk equivalent, for risk factor 
management. The principal reason to evaluate dyslipidemias in patients with 
CKD is to detect abnormalities that may be treated to reduce the incidence 
of ACVD (Atherosclerotic Cardiovascular Disease).  The appropriate 
management of dyslipidemia plays an important role in the overall care of 
the patient with chronic and ESRD and renal transplantation. Evaluation of 
dyslipidemias should occur at presentation with chronic renal disease, 
following a change in treatment modality and annually. The American 
Society  of Transplantation recommend tha a lipid profile should be 
measured during the first 6 months post transplant, at 1 year after transplant 
and annually thereafter.  Appropiate therapeutic life style change and drug 
therapy should be started. LDL level should be maintained below 100mg/dl, 
Triglycerides below 150 mg/dl and HDL should be above 40. Drug therapy 
should be used for LDL levels of 130 mg/dl and also for LDL levels of 100-
129 mg/dl after 3 month of therapeutic life style change. 
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CONCLUSION 
 
¾ There is no significant difference in the lipid profile between males 
and females in the different groups except for triglyceride level in 
conservative group. 
¾ The mean total cholesterol is significantly increased in chronic kidney 
disease patients on conservative group, on haemodialysis group and 
post transplant group when compared to controls (p<0.001). Among 
the three groups total cholesterol is significantly increased in post 
transplant group. 
¾ The mean triglyceride level is significantly increased in CKD patients 
on conservative management (p<0.001), on haemodialysis (p<0.001) 
and after transplantation (p<0.001). According to ATP III guidelines 
the mean triglycerides is high (> 200mg/dl) in post transplant group 
and border line high (150-199) in the conservative and haemodialysis 
group. 
¾ The mean LDL cholesterol is significantly increased in the post 
transplantation group, on haemodialyis group and conservative group.  
As per ATP III guidelines the mean LDL cholesterol is high (> 
100mg/dl) in the post transplant group.  
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¾ The mean HDL cholesterol is significantly decreased in the 
conservative management group (p<0.001), the hemodialysis group 
(p<0.001) and in the post transplant group (p<0.001). 
¾ The total cholesterol to HDL cholesterol ratio is significantly 
increased in CKD patients on conservative management (p<0.001), 
on haemodialysis (p<0.001) and after transplantation (p<0.001). 
Among the three groups  the ratio is significantly increased in post 
transplant group.  
              Dyslipidemia is a very common complication of CKD. Disturbance 
in lipoprotein metabolism usually follow a downhill course that parallels the 
deterioration in renal function.The lipoprotein abnormalities caused by renal 
insufficiency also may further influence the progression of renal failure.   
Since dyslipidemia and its complications are more prevalent in chronic 
kidney disease patients, early diagnosis of dyslipidemia is indicated and 
potential therapeutic approaches (therapeutic life style changes and 
pharmacotherapy) should be initiated to limit the long term consequences of 
cardiovascular disease in this population of patients, whose longevity is 
anticipated to increase with dialysis and transplantation. 
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LIMITATIONS OF THE STUDY 
 
1. Sample size in our study is relatively small. 
2. Staging of CKD and dyslipidemia are not correlated in this 
study. 
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PROFORMA 
 
NAME : 
AGE : 
SEX : 
HISTORY OF DIABETES   -    PRESENT / ABSENT 
HISTORY OF HYPERTENSION  -  PRESENT / ABSENT  
CHRONIC KIDNEY DISEASE 
DURATION:  
TREATMENT:   
1. CONSERVATIVE  
2. HAEMODIALYSIS  
3. RENAL TRANSPLANTATION 
LABORATORY INVESTIGATIONS: 
1.  BLOOD UREA: 
2.  SERUM CREATININE: 
3.  FASTING LIPID PROFILE: 
4.  TOTAL CHOLESTEROL /HDL RATIO: 
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ABBREVIATIONS 
 
CKD   -  Chronic Kidney Disease  
ESRD  -  End stage renal disease 
TG  -  Triglyceride 
TC   -  Total cholesterol 
HDL   - High density lipoprotein 
LDL   -  Low density lipoprotein 
VLDL -  Very low density lipoprotein 
HD   -  Hemodialysis 
LPL   -  Lipoprotein lipase 
LCAT -  Lecithin cholesterol acyl transferase 
ACAT - acyl-CoA cholesterol acyltransferase 
CETP  -  Cholesteryl ester transfer protein 
ACVD -  Atherosclerotic Cardiovascular Disease 
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MASTER CHART 
CKD  CONSERVATIVE MANAGEMENT 
S.No. Name Sex Age TChl TGL HDL LDL TChl/HDL 
1 Arumugam M 41 172.00 180.00 36.00 100.00 4.8 
2 Ramu M 40 164.00 175.00 37.00 92.00 4.4 
3 Mookan M 39 163.00 160.00 38.00 93.00 4.3 
4 Thangaraj M 40 166.00 180.00 35.00 95.00 4.7 
5 Alagarsamy M 40 162.00 170.00 34.00 94.00 4.8 
6 Ganesan M 41 156.00 160.00 36.00 90.00 4.3 
7 Muniasamy M 39 148.00 158.00 35.00 81.00 4.2 
8 Ponnaiah M 42 158.00 146.00 36.00 94.00 4.4 
9 Thangam M 38 162.00 146.00 37.00 97.00 4.4 
10 Ravikumar M 48 154.00 156.00 37.00 89.00 4.2 
11 petchiammal F 42 160.00 148.00 35.00 97.00 4.6 
12 muthal F 45 150.00 140.00 36.00 87.00 4.2 
13 karupaiye F 36 148.00 140.00 34.00 84.00 4.4 
14 lakshmi F 47 160.00 142.00 36.00 98.00 4.4 
15 muniammal F 43 164.00 146.00 35.00 99.00 4.7 
16 rakkammal F 35 166.00 146.00 36.00 102.00 4.6 
17 thenmozhi F 48 156.00 142.00 40.00 92.00 3.9 
18 vasantha F 39 146.00 138.00 42.00 79.00 3.5 
19 meena F 46 162.00 150.00 36.00 96.00 4.5 
20 princemarry F 46 152.00 148.00 35.00 88.00 4.3 
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Post Transplant 
S.No. Name Sex Age TChl TGL HDL LDL TChl/HDL 
1 Saleem M 37 200 332 40 94 5.0 
2 Saktheswaran M 32 180 231 40 94 4.5 
3 Ellareddy M 42 167 185 36 94 4.6 
4 Saravanan M 40 174 150 39 105 4.5 
5 Guruchandran M 38 172 166 37 103 4.6 
6 Nataraj M 39 202 240 40 114 5.1 
7 Prabhakaran M 45 187 208 35 110 5.3 
8 Suresh M 30 190 254 40 99 4.8 
9 Raman M 29 228 170 37 157 6.2 
10 Bharathi M 37 168 167 35 99 4.8 
11 jameela F 41 189 226 37 107 5.1 
12 jeeva F 35 209 228 40 123 5.2 
13 kala F 40 174 169 35 112 5.0 
14 ramya F 42 180 200 40 100 4.5 
15 Ramani F 38 177 166 39 105 4.5 
16 Ambiga F 42 196 208 37 117 5.3 
17 Chandra F 36 179 226 37 97 4.8 
18 Tamilselvi F 42 179 185 40 102 4.5 
19 Parvathi F 38 232 204 37 154 6.3 
20 Suganya F 41 220 250 37 133 5.9 
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CKD Hemodialysis 
S.No. Name Sex Age TChl TGL HDL LDL TChl/HDL 
1 Thothan M 45 140 158 42 69 3.3 
2 Murugan M 35 203 190 37 128 5.5 
3 Palani M 41 138 154 36 72 3.8 
4 Rajan M 42 136 150 37 69 3.7 
5 Kanan M 38 135 148 34 72 4.0 
6 Balamurugan M 41 140 156 38 71 3.7 
7 Kuppaiah M 46 142 155 33 78 4.3 
8 Elango M 39 148 170 34 80 4.4 
9 Karthikpandi M 41 146 162 35 78 4.2 
10 Manikandan M 37 150 168 36 82 4.2 
11 Rani F 38 144 166 41 70 3.5 
12 Paalaniyammal F 42 140 163 34 74 4.1 
13 Jansi F 40 136 170 35 67 3.9 
14 Shanthi F 41 135 168 33 69 4.1 
15 Priya F 37 142 163 34 76 4.2 
16 Rajammal F 42 146 164 36 77 4.1 
17 Jeena F 38 201 172 42 125 4.8 
18 Lurthubegam F 28 136 156 34 71 4.0 
19 Lakshmirani F 32 138 154 38 70 3.6 
20 Durga F 36 150 149 36 78 4.2 
 
 
 
  83 
 
 
CONTROL GROUP 
S.No. Name Sex Age TChl TGL HDL LDL TChl/HDL 
1 Abubakar M 40 152 128 42 84 3.6 
2 Murugapandi M 27 115 100 45 50 2.6 
3 Venkatesh M 42 127 100 43 64 3.0 
4 Ganesan M 45 112 120 40 48 2.8 
5 Arumugam M 40 124 100 46 58 2.7 
6 Arokiadass M 38 132 112 48 68 2.8 
7 Ibraheem M 42 126 110 42 62 3.0 
8 Raman M 46 119 120 44 51 2.7 
9 Muthupandi M 39 120 128 42 52 2.9 
10 Karthikeyan M 39 128 130 50 52 2.6 
11 manimegalai F  42 128 151 42 56 3.0 
12 Pavithra F  47 131 136 44 60 3.0 
13 Alamelu F  42 138 142 48 62 2.9 
14 Mookammal F  38 129 126 40 64 3.2 
15 Muthupechi F  39 120 132 42 51 2.9 
16 Renuga F  29 132 117 43 62 3.1 
17 Vadivu F  42 128 118 45 59 2.8 
18 Ratha F  40 126 116 47 56 2.7 
19 Punitha F  38 118 107 40 56 3.0 
20 Amutha F  36 127 112 41 63 3.1 
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